Revista de SIDA e investigación clínica

La aparición de la pandemia de COVID-19 causada por el nuevo coronavirus SARS-CoV-2 ha puesto de relieve la urgente necesidad de contar con terapias antivirales y vacunas eficaces. En el mundo de la virología, las lecciones aprendidas en la lucha contra otras infecciones virales, como el VIH, pueden proporcionar información valiosa. Una línea de investigación interesante es el posible uso de la terapia con péptidos Ezrin para inhibir la inflamación y ampliar la inmunidad antiviral adaptativa en una variedad de infecciones virales, incluidas tanto el VIH como la COVID-19.

El VIH, el virus de inmunodeficiencia humana, sigue siendo un problema de salud mundial que afecta a millones de personas en todo el mundo. Aunque se ha avanzado mucho en la comprensión del virus y en el desarrollo de terapias antirretrovirales, todavía hay muchos aspectos de la infección por VIH que requieren más investigación. Uno de ellos es el impacto del VIH en la mucosa intestinal y su papel en la translocación de macromoléculas a través de fugas apoptóticas y transcitosis. Con la llegada de una terapia antirretroviral eficaz, la esperanza de vida de las personas que viven con el VIH ha mejorado sustancialmente. Sin embargo, esta población se enfrenta ahora a nuevos retos, incluido un mayor riesgo de desarrollar ciertos tipos de cáncer. En esta sección se presenta el tema y se destaca la importancia de comprender la evolución de la incidencia del cáncer en diferentes períodos del tratamiento antirretroviral.

Human Immunodeficiency Virus (HIV) remains a global health challenge, affecting millions of people worldwide. The advent of Highly Active Antiretroviral Therapy (HAART) has transformed HIV infection from a life-threatening disease to a manageable chronic condition, significantly improving the life expectancy and quality of life for individuals living with HIV. Vaccinations play a critical role in safeguarding the health of this vulnerable population, helping to prevent potentially life-threatening infections.

HIV/AIDS remains a global public health challenge, with millions of people worldwide living with the virus. Effective Antiretroviral Therapy (ART) has transformed HIV into a manageable chronic condition, enhancing the quality of life and extending the lifespan of those affected. However, the emergence of drug resistance mutations in the HIV-1 virus poses a significant threat to the success of ART. This article delves into a study conducted in Russia's Northwestern Federal District, focusing on the prevalence and implications of HIV-1 drug resistance mutations among patients experiencing treatment failure. Russia has been grappling with an expanding HIV epidemic for several years. The country has the highest number of new HIV infections in Eastern Europe and Central Asia, with the Northwestern Federal District being one of the regions most severely affected.

In 2015, a cross-sectional study was conducted in Zhejiang, China, to investigate the prevalence of active syphilis infection among HIV-positive men who have sex with men and to identify the associated risk factors. This study sheds light on the intersecting challenges faced by individuals in this vulnerable population and provides valuable insights into the dynamics of Sexually Transmitted Infections (STIs) within the context of HIV in the region. The HIV epidemic in China has been on the rise, particularly among MSM. Simultaneously, the prevalence of syphilis, a bacterial STI, has also been increasing in various parts of the country. Understanding the prevalence and risk factors associated with active syphilis infection in HIV-positive MSM is critical for public health efforts aimed at prevention, diagnosis and treatment.

The quest for an effective HIV vaccine has been ongoing for decades, and despite significant progress in understanding the virus and developing prevention and treatment strategies, a prophylactic vaccine remains elusive. Heterologous prime-boost vaccination strategies, involving the use of different vaccine vectors for initial priming and subsequent boosting, have shown promise in inducing robust and durable immune responses. This article explores the evaluation of a novel approach: using Lumpy Skin Disease Virus (LSDV) as a vector for heterologous prime-boost HIV immunizations. HIV (Human Immunodeficiency Virus) is a complex and highly mutable virus that has defied conventional vaccine development strategies.

The HIV/AIDS epidemic is a global health crisis that affects diverse populations worldwide. In this article, we focus on the specific context of Minnesota, where a significant population of refugees has been affected by HIV/AIDS from 2000 to 2007. We explore the challenges and unique factors influencing the spread and management of HIV/AIDS in this community, examining both medical and social aspects. The analysis draws attention to the need for culturally sensitive healthcare, education, and support programs to address the distinct needs of Minnesota's HIV-infected refugee population.

HIV-1 infection remains a global health challenge, affecting millions of people worldwide. While much progress has been made in managing and treating HIV-1, co-infections and comorbidities continue to pose significant concerns. One such issue is the immune response to Hepatitis B Virus (HBV) vaccination in HIV-1-infected individuals. This article explores the phenomenon of undetectable anti-HBs antibodies in HIV-1-infected individuals and discusses the potential need for booster doses of HBV vaccine to ensure long-term protection. The quest for an effective HIV vaccine has been one of the greatest challenges in modern medicine.

La infección por VIH-1 sigue siendo un problema de salud mundial, ya que aproximadamente 38 millones de personas viven con el virus en todo el mundo. Si bien la llegada de la terapia antirretroviral de gran actividad (TARGA) ha mejorado significativamente el pronóstico y la calidad de vida de las personas que viven con VIH-1, la cura completa sigue siendo difícil de alcanzar debido a la persistencia de reservorios latentes del VIH-1. La latencia del VIH-1 se refiere a la capacidad del virus de permanecer inactivo en ciertas células, evadiendo la vigilancia inmunológica y los medicamentos antirretrovirales. Este reservorio latente plantea una barrera importante para lograr una cura funcional para el VIH-1. En esta revisión, profundizamos en los mecanismos moleculares subyacentes a la latencia del VIH-1 y analizamos los enfoques terapéuticos actuales destinados a erradicar o controlar este reservorio persistente.